Indaptus Therapeutics, Inc. (INDP) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Indaptus Therapeutics (INDP) aims for the global implementation of its Decoy platform, which activates anti-tumor immunity via bacterial components. This chart of EV/EBITDA price action, with a value of 0.00, reflects operations within the biopharmaceuticals and oncology center segment, where profits are generated through innovative therapy methods. The stability of business processes is ensured by the reliability of high-precision equipment and strict adherence to schedules at partner manufacturing plants.
indaptusrx.com - analytical breakdowns and key metrics (INDP)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Indaptus Therapeutics|INDP - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Indaptus Therapeutics, Inc.|INDP - Company Cumulative Debt|Debts to Book Capitalization Indaptus Corp|INDP - Long-Term Debt Volume|Company Short-Term Debt Indaptus Therapeutics|Quick Ratio indaptusrx.com
- business earnings and investment ratios data:
INDP - Company Profit|Projected Future Earnings Indaptus Therapeutics|INDP - P/E Multiple|Future Price to Earnings Indaptus Therapeutics|INDP - Market Cap to Earnings and Growth Ratio|Enterprise Value to EBITDA Ratio Indaptus Corp|INDP - Company profit before taxes, interest and amortization|Net earnings per share for the last 12 months Indaptus Therapeutics|INDP - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months indaptusrx.com|INDP - Expected net earnings per share growth this year|Expected earnings per share growth for next year Indaptus Therapeutics
Initial company analysis:Indaptus INDP
For the capital-intensive Indaptus Therapeutics (INDP), the EV/EBITDA multiple serves as a tool for valuing the business by accounting for net debt relative to operating profit. This metric compares the total market value of the asset with its ability to generate cash flow before taxes, depreciation, and amortization. By analyzing the EV/EBITDA trend, an investor can assess the company's resilience amid geopolitical risks that are hindering the international registration of immunotherapy drugs.
Analysis of competing companies
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|Vera Pharma - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Dianthus Corp DNTH|Pharvaris N.V. (PHVS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation ABCL|TRML (Tourmaline Bio) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation PGEN (Precigen Inc)|EV/EBITDA Multiple PHAR|EV/EBITDA Multiple Nektar Corp (NKTR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Upstream Bio Inc UPB|ZBIO (zenasbio.com) - Company Value to Operating Income Before Depreciation Ratio|IMNM: Enterprise Value to EBITDA Ratio|Gossamer Bio Inc - Enterprise Value to Operating Income Before Depreciation Ratio|KALV (KalVista Pharmaceuticals Inc) - Enterprise Value to EBITDA Ratio|Septerna Pharma (SEPN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals|savarapharma.com (SVRA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio RIGL (Rigel Pharmaceuticals, Inc.)|ANAB (AnaptysBio Inc) - Business Value to Operating Income Before Depreciation|Astria Pharma - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ENGN (enGene Corp)|RAPT Therapeutics - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation JBIO (Aerovate Therapeutics Inc)|ACRS: EV/EBITDA Multiple|Company Value to EBITDA Kyverna Therapeutics Inc. (KYTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tiziana Life Sciences PLC|CABA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple VTYX|EV/EBITDA Multiple theratech.com (THTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avalo Therapeutics AVTX|ELDN (Eledon Pharmaceuticals Inc.) - Company Value to Operating Income Before Depreciation Ratio|Agenus Inc - EV/EBITDA Multiple|Company Value to EBITDA Climb Bio, Inc|ZURA (Zura Bio) - Enterprise Value to EBITDA Ratio|atyrpharma.com (ATYR) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio ADAG|IMA (Ikena Oncology, Inc.) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple STTK|Total Company Value to Operating Income Before Depreciation Ratio equilliumbio.com|EV/EBITDA Multiple CNTB (Connect Biopharma Holdings Limited)|IMUX - Enterprise Value to EBITDA Ratio|ATRA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio InflaRx N.V. IFRX|XFOR: EV/EBITDA Multiple|ACET - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Celularity Inc|Enterprise Value to Operating Income Before Depreciation INMB (inmunebio.com)|EV/EBITDA Multiple BRNS|Kezar Life Sciences Inc. - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SAB Biotherapeutics, Inc SABS|AKTX (Akari Therapeutics, Plc) - Company Value to Operating Income Before Depreciation Ratio|ENLV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio QTTB|GOVX: EV/EBITDA Multiple|Edesa Biotech Inc - Business Value to Operating Income Before Depreciation|IBIO (iBio Corp) - EV/EBITDA Multiple|EV/EBITDA Multiple Carisma Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization XTL Biopharmaceuticals (XTLB)|BOLT (boltbio.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization HCW Biologics HCWB|APVO - Enterprise Value to EBITDA Ratio|AIM ImmunoTech Inc. - EV/EBITDA Multiple|ADTX - EV/EBITDA Multiple|GRI (GRI Bio, Inc.) - Enterprise Value to EBITDA Ratio|xortx.com - Business Value to Operating Income Before Depreciation|HIND (Vyome Holdings) - EV/EBITDA Multiple|Revelation Biosciences Inc (REVB) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Scinai (SCNI)|Enterprise Value to EBITDA Ratio calcimedica.com CALI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Affimed N.V. AFMD|ALLK - Enterprise Value to EBITDA Ratio|HOOK: Enterprise Value to EBITDA Ratio|IGMS - EV/EBITDA Multiple|iTeos (ITOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation OCEA|TCBP (TC Biopharm) - EV/EBITDA Multiple|Company Value to EBITDA thirdharmonicbio.com THRD
